Enliven Therapeutics (ELVN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Enliven Therapeutics (ELVN) is Neutral.

The composite score behind that read is -0.18, weighing +0.22 of bullish evidence against -0.43 bearish.

Enliven Therapeutics last closed at $45.47, -3.19% on the session.

Against the IVW growth benchmark the position is -4.11% over the forecast window.

The read is built from 11 underlying insights — 4 bullish and 7 bearish.

Agreement across those insights is 64%.

Enliven Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Enliven Therapeutics in the 28th percentile on return on equity, where 100 is best.

Enliven Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $3.44B.

StockMap tracks Enliven Therapeutics as the 29th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Enliven Therapeutics ranks 56th of 128 in the group, against a group median of -0.24.